Jazz Pharmaceuticals price target raised to $205 from $200 at Truist

Truist analyst Joon Lee raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $205 from $200 and keeps a Buy rating on the shares. The firm cites the company’s webcast to highlight commercial strategy for the recently approved Modeyso, dordaviprone, for an ultra-rare form of aggressive glioma – H3 K27M mutation. The lack of competition for this high unmet need in a highly lethal brain tumor sets up Modeyso for robust commercial uptake, the analyst tells investors in a research note.